CTNNB1 and hepatocellular carcinoma: Regarding HCC cases, Montironi et al. characterized the immunogenomic context of tumors and classified 37% of the tumors into an “inflamed” group and 63% into a “non-inflamed” group, where a majority of CTNNB1 mutations were associated with non-inflamed tumors [19].